{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:37:50Z","timestamp":1794451070600,"version":"4.9.1"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Early evaluation of treatment response and prediction of disease evolution are key issues in the management of people with multiple sclerosis (MS). In the past 20 years, MRI has become the most useful paraclinical tool in both situations and is used clinically to assess the inflammatory component of the disease, particularly the presence and evolution of focal lesions \u2014 the pathological hallmark of MS. However, diffuse neurodegenerative processes that are at least partly independent of inflammatory mechanisms can develop early in people with MS and are closely related to disability. The effects of these neurodegenerative processes at a macroscopic level can be quantified by estimation of brain and spinal cord atrophy with MRI. MRI measurements of atrophy in MS have also been proposed as a complementary approach to lesion assessment to facilitate the prediction of clinical outcomes and to assess treatment responses. In this Consensus statement, the Magnetic Resonance Imaging in MS (MAGNIMS) study group critically review the application of brain and spinal cord atrophy in clinical practice in the management of MS, considering the role of atrophy measures in prognosis and treatment monitoring and the barriers to clinical use of these measures. On the basis of this review, the group makes consensus statements and recommendations for future research.<\/jats:p>","DOI":"10.1038\/s41582-020-0314-x","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T07:07:06Z","timestamp":1582528026000},"page":"171-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":274,"title":["MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice"],"prefix":"10.1038","volume":"16","author":[{"name":"on behalf of the MAGNIMS study group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1589-2254","authenticated-orcid":false,"given":"Jaume","family":"Sastre-Garriga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Pareto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Battaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-4320","authenticated-orcid":false,"given":"Maria A.","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Enzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wuerfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A.","family":"Yousry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-5359","authenticated-orcid":false,"given":"Mar","family":"Tintor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Vrenken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c0lex","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"314_CR1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","volume":"88","author":"I Kawachi","year":"2017","unstructured":"Kawachi, I. & Lassmann, H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 88, 137\u2013145 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"314_CR2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/brain\/120.3.393","volume":"120","author":"B Ferguson","year":"1997","unstructured":"Ferguson, B., Matyszak, M. K., Esiri, M. M. & Perry, V. H. Axonal damage in acute multiple sclerosis lesions. Brain 120, 393\u2013399 (1997).","journal-title":"Brain"},{"key":"314_CR3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"BD Trapp","year":"1998","unstructured":"Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278\u2013285 (1998).","journal-title":"N. Engl. J. Med."},{"key":"314_CR4","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1093\/brain\/awf235","volume":"125","author":"T Kuhlmann","year":"2002","unstructured":"Kuhlmann, T., Lingfeld, G., Bitsch, A., Schuchardt, J. & Bruck, W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125, 2202\u20132212 (2002).","journal-title":"Brain"},{"key":"314_CR5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B","volume":"48","author":"C Bjartmar","year":"2000","unstructured":"Bjartmar, C., Kidd, G., Mork, S., Rudick, R. & Trapp, B. D. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 48, 893\u2013901 (2000).","journal-title":"Ann. Neurol."},{"key":"314_CR6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/1352458514556300","volume":"21","author":"J Sastre-Garriga","year":"2015","unstructured":"Sastre-Garriga, J. et al. Brain atrophy in natalizumab-treated patients: a 3-year follow-up. Mult. Scler. 21, 749\u2013756 (2015).","journal-title":"Mult. Scler."},{"key":"314_CR7","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/hbm.23168","volume":"37","author":"V Popescu","year":"2016","unstructured":"Popescu, V. et al. Postmortem validation of MRI cortical volume measurements in MS. Hum. Brain Mapp. 37, 2223\u20132233 (2016).","journal-title":"Hum. Brain Mapp."},{"key":"314_CR8","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/brain\/119.6.2009","volume":"119","author":"NA Losseff","year":"1996","unstructured":"Losseff, N. A. et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119, 2009\u20132019 (1996).","journal-title":"Brain"},{"key":"314_CR9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/brain\/119.3.701","volume":"119","author":"NA Losseff","year":"1996","unstructured":"Losseff, N. A. et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119, 701\u2013708 (1996).","journal-title":"Brain"},{"key":"314_CR10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ana.410390104","volume":"39","author":"DH Miller","year":"1996","unstructured":"Miller, D. H. et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society task force. Ann. Neurol. 39, 6\u201316 (1996).","journal-title":"Ann. Neurol."},{"key":"314_CR11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2017","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2017).","journal-title":"Lancet Neurol."},{"key":"314_CR12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald, W. I. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121\u2013127 (2001).","journal-title":"Ann. Neurol."},{"key":"314_CR13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278\u2013286 (2014).","journal-title":"Neurology"},{"key":"314_CR14","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/brain\/awf177","volume":"125","author":"DH Miller","year":"2002","unstructured":"Miller, D. H., Barkhof, F., Frank, J. A., Parker, G. J. & Thompson, A. J. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125, 1676\u20131695 (2002).","journal-title":"Brain"},{"key":"314_CR15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0000000000003542","volume":"88","author":"MA Rocca","year":"2017","unstructured":"Rocca, M. A. et al. Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology 88, 403\u2013413 (2017).","journal-title":"Neurology"},{"key":"314_CR16","first-page":"597","volume":"11","author":"MP Wattjes","year":"2015","unstructured":"Wattjes, M. P. et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis \u2014 establishing disease prognosis and monitoring patients. Nat. Rev. Neurol. 11, 597\u2013606 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"314_CR17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrneurol.2015.106","volume":"11","author":"A Rovira","year":"2015","unstructured":"Rovira, A. et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis \u2014 clinical implementation in the diagnostic process. Nat. Rev. Neurol. 11, 471\u2013482 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"314_CR18","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/archneur.1985.04060070068018","volume":"42","author":"SM Rao","year":"1985","unstructured":"Rao, S. M. et al. Chronic progressive multiple sclerosis. Relationship between cerebral ventricular size and neuropsychological impairment. Arch. Neurol. 42, 678\u2013682 (1985).","journal-title":"Arch. Neurol."},{"key":"314_CR19","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/0022-510X(93)90212-H","volume":"115","author":"G Comi","year":"1993","unstructured":"Comi, G. et al. Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. J. Neurol. Sci. 115, S66\u2013S73 (1993).","journal-title":"J. Neurol. Sci."},{"key":"314_CR20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/archneur.1987.00520190040015","volume":"44","author":"SJ Huber","year":"1987","unstructured":"Huber, S. J. et al. Magnetic resonance imaging correlates of dementia in multiple sclerosis. Arch. Neurol. 44, 732\u2013736 (1987).","journal-title":"Arch. Neurol."},{"key":"314_CR21","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/WNL.0b013e3181e24136","volume":"74","author":"N De Stefano","year":"2010","unstructured":"De Stefano, N. et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74, 1868\u20131876 (2010).","journal-title":"Neurology"},{"key":"314_CR22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/WNL.0b013e31824528c9","volume":"78","author":"MP Amato","year":"2012","unstructured":"Amato, M. P. et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology 78, 309\u2013314 (2012).","journal-title":"Neurology"},{"key":"314_CR23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neurobiolaging.2019.05.010","volume":"81","author":"M Battaglini","year":"2019","unstructured":"Battaglini, M. et al. Lifespan normative data on rates of brain volume changes. Neurobiol. Aging 81, 30\u201337 (2019).","journal-title":"Neurobiol. Aging"},{"key":"314_CR24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jnnp-2016-314597.33","volume":"87","author":"N De Stefano","year":"2016","unstructured":"De Stefano, N. et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 87, 93\u201399 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"314_CR25","volume":"2","author":"FC Perez-Miralles","year":"2015","unstructured":"Perez-Miralles, F. C. et al. Predictive value of early brain atrophy on response in patients treated with interferon beta. Neurol. Neuroimmunol. Neuroinflamm. 2, e132 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"314_CR26","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jamaneurol.2018.1596","volume":"75","author":"M Andorra","year":"2018","unstructured":"Andorra, M. et al. Assessing biological and methodological aspects of brain volume loss in multiple sclerosis. JAMA Neurol. 75, 1246\u20131255 (2018).","journal-title":"JAMA Neurol."},{"key":"314_CR27","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1177\/1352458513488231","volume":"19","author":"F Perez-Miralles","year":"2013","unstructured":"Perez-Miralles, F. et al. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult. Scler. 19, 1878\u20131886 (2013).","journal-title":"Mult. Scler."},{"key":"314_CR28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/jnnp.2009.171769","volume":"81","author":"M Di Filippo","year":"2010","unstructured":"Di Filippo, M. et al. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J. Neurol. Neurosurg. Psychiatry 81, 204\u2013208 (2010).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"314_CR29","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/jnnp.2007.124123","volume":"79","author":"A Minneboo","year":"2008","unstructured":"Minneboo, A. et al. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. J. Neurol. Neurosurg. Psychiatry 79, 917\u2013923 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"314_CR30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1212\/01.wnl.0000173061.12776.1f","volume":"65","author":"J Sastre-Garriga","year":"2005","unstructured":"Sastre-Garriga, J. et al. Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology 65, 633\u2013635 (2005).","journal-title":"Neurology"},{"key":"314_CR31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ana.21375","volume":"63","author":"Z Khaleeli","year":"2008","unstructured":"Khaleeli, Z. et al. Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. Ann. Neurol. 63, 790\u2013793 (2008).","journal-title":"Ann. Neurol."},{"key":"314_CR32","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/brain\/awx250","volume":"140","author":"MA Rocca","year":"2017","unstructured":"Rocca, M. A. et al. Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. Brain 140, 2814\u20132819 (2017).","journal-title":"Brain"},{"key":"314_CR33","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1136\/jnnp-2012-304094","volume":"84","author":"V Popescu","year":"2013","unstructured":"Popescu, V. et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 84, 1082\u20131091 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"314_CR34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/acn3.534","volume":"5","author":"DH Miller","year":"2018","unstructured":"Miller, D. H. et al. Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. Ann. Clin. Transl. Neurol. 5, 346\u2013356 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"314_CR35","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/1352458516659550","volume":"23","author":"MP Sormani","year":"2017","unstructured":"Sormani, M. P. et al. Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. Mult. Scler. 23, 656\u2013664 (2017).","journal-title":"Mult. Scler."},{"key":"314_CR36","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1177\/1352458514533399","volume":"20","author":"M Daams","year":"2014","unstructured":"Daams, M. et al. Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: relation to brain findings and clinical disability. Mult. Scler. 20, 1860\u20131865 (2014).","journal-title":"Mult. Scler."},{"key":"314_CR37","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp.2006.094748","volume":"77","author":"M Bieniek","year":"2006","unstructured":"Bieniek, M. et al. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 77, 1036\u20131039 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"314_CR38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1148\/radiol.13122566","volume":"269","author":"C Lukas","year":"2013","unstructured":"Lukas, C. et al. Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology 269, 542\u2013552 (2013).","journal-title":"Radiology"},{"key":"314_CR39","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1212\/WNL.0b013e31821f46b8","volume":"76","author":"MA Rocca","year":"2011","unstructured":"Rocca, M. A. et al. A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. Neurology 76, 2096\u20132102 (2011).","journal-title":"Neurology"},{"key":"314_CR40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1212\/WNL.0000000000001756","volume":"85","author":"M Daams","year":"2015","unstructured":"Daams, M. et al. Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis. Neurology 85, 248\u2013255 (2015).","journal-title":"Neurology"},{"key":"314_CR41","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1212\/WNL.0000000000001257","volume":"84","author":"J Oh","year":"2015","unstructured":"Oh, J. et al. Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis. Neurology 84, 720\u2013728 (2015).","journal-title":"Neurology"},{"key":"314_CR42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458513492245","volume":"20","author":"H Kearney","year":"2014","unstructured":"Kearney, H. et al. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult. Scler. 20, 72\u201380 (2014).","journal-title":"Mult. Scler."},{"key":"314_CR43","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1212\/WNL.0000000000005853","volume":"91","author":"C Tsagkas","year":"2018","unstructured":"Tsagkas, C. et al. Spinal cord volume loss: a marker of disease progression in multiple sclerosis. Neurology 91, e349\u2013e358 (2018).","journal-title":"Neurology"},{"key":"314_CR44","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ana.24241","volume":"76","author":"R Schlaeger","year":"2014","unstructured":"Schlaeger, R. et al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann. Neurol. 76, 568\u2013580 (2014).","journal-title":"Ann. Neurol."},{"key":"314_CR45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105544","volume":"9","author":"MC Yiannakas","year":"2014","unstructured":"Yiannakas, M. C., Kakar, P., Hoy, L. R., Miller, D. H. & Wheeler-Kingshott, C. A. The use of the lumbosacral enlargement as an intrinsic imaging biomarker: feasibility of grey matter and white matter cross-sectional area measurements using MRI at 3\u2009T. PLoS One 9, e105544 (2014).","journal-title":"PLoS One"},{"key":"314_CR46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp-2012-303821","volume":"84","author":"MA Rocca","year":"2013","unstructured":"Rocca, M. A. et al. Voxel-wise mapping of cervical cord damage in multiple sclerosis patients with different clinical phenotypes. J. Neurol. Neurosurg. Psychiatry 84, 35\u201341 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"314_CR47","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/jnnp-2014-308021","volume":"86","author":"C Lukas","year":"2015","unstructured":"Lukas, C. et al. Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 86, 410\u2013418 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"314_CR48","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1352458518775006","volume":"25","author":"C Tsagkas","year":"2019","unstructured":"Tsagkas, C. et al. Preferential spinal cord volume loss in primary progressive multiple sclerosis. Mult. Scler. 25, 947\u2013957 (2019).","journal-title":"Mult. Scler."},{"key":"314_CR49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1212\/WNL.0000000000001186","volume":"84","author":"H Kearney","year":"2015","unstructured":"Kearney, H. et al. Cervical cord lesion load is associated with disability independently from atrophy in MS. Neurology 84, 367\u2013373 (2015).","journal-title":"Neurology"},{"key":"314_CR50","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/brain\/awf025","volume":"125","author":"DT Chard","year":"2002","unstructured":"Chard, D. T. et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 125, 327\u2013337 (2002).","journal-title":"Brain"},{"key":"314_CR51","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.neuroimage.2004.02.008","volume":"22","author":"J Sastre-Garriga","year":"2004","unstructured":"Sastre-Garriga, J. et al. Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage 22, 353\u2013359 (2004).","journal-title":"Neuroimage"},{"key":"314_CR52","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1212\/01.WNL.0000055926.69643.03","volume":"60","author":"N De Stefano","year":"2003","unstructured":"De Stefano, N. et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 60, 1157\u20131162 (2003).","journal-title":"Neurology"},{"key":"314_CR53","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S1053-8119(02)00018-6","volume":"18","author":"M Quarantelli","year":"2003","unstructured":"Quarantelli, M. et al. Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. Neuroimage 18, 360\u2013366 (2003).","journal-title":"Neuroimage"},{"key":"314_CR54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ana.21436","volume":"64","author":"E Fisher","year":"2008","unstructured":"Fisher, E., Lee, J. C., Nakamura, K. & Rudick, R. A. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann. Neurol. 64, 255\u2013265 (2008).","journal-title":"Ann. Neurol."},{"key":"314_CR55","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1177\/1352458511404916","volume":"17","author":"SD Roosendaal","year":"2011","unstructured":"Roosendaal, S. D. et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult. Scler. 17, 1098\u20131106 (2011).","journal-title":"Mult. Scler."},{"key":"314_CR56","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/brain\/awh126","volume":"127","author":"CM Dalton","year":"2004","unstructured":"Dalton, C. M. et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 127, 1101\u20131107 (2004).","journal-title":"Brain"},{"key":"314_CR57","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1212\/01.wnl.0000178982.53965.70","volume":"65","author":"P Valsasina","year":"2005","unstructured":"Valsasina, P. et al. Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology 65, 1126\u20131128 (2005).","journal-title":"Neurology"},{"key":"314_CR58","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1212\/01.WNL.0000154526.22878.30","volume":"64","author":"M Tiberio","year":"2005","unstructured":"Tiberio, M. et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 64, 1001\u20131007 (2005).","journal-title":"Neurology"},{"key":"314_CR59","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/brain\/awh498","volume":"128","author":"J Sastre-Garriga","year":"2005","unstructured":"Sastre-Garriga, J. et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain 128, 1454\u20131460 (2005).","journal-title":"Brain"},{"key":"314_CR60","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.21423","volume":"64","author":"LK Fisniku","year":"2008","unstructured":"Fisniku, L. K. et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann. Neurol. 64, 247\u2013254 (2008).","journal-title":"Ann. Neurol."},{"key":"314_CR61","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1212\/01.wnl.0000435551.90824.d0","volume":"81","author":"M Filippi","year":"2013","unstructured":"Filippi, M. et al. Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology 81, 1759\u20131767 (2013).","journal-title":"Neurology"},{"key":"314_CR62","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/jnnp-2013-306906","volume":"85","author":"C Jacobsen","year":"2014","unstructured":"Jacobsen, C. et al. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J. Neurol. Neurosurg. Psychiatry 85, 1109\u20131115 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"314_CR63","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.nicl.2012.11.009","volume":"2","author":"PA Narayana","year":"2012","unstructured":"Narayana, P. A. et al. Regional cortical thickness in relapsing remitting multiple sclerosis: a multi-center study. Neuroimage Clin. 2, 120\u2013131 (2012).","journal-title":"Neuroimage Clin."},{"key":"314_CR64","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.neubiorev.2013.03.006","volume":"37","author":"J Lansley","year":"2013","unstructured":"Lansley, J., Mataix-Cols, D., Grau, M., Radua, J. & Sastre-Garriga, J. Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. Neurosci. Biobehav. Rev. 37, 819\u2013830 (2013).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"314_CR65","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ana.25145","volume":"83","author":"A Eshaghi","year":"2018","unstructured":"Eshaghi, A. et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann. Neurol. 83, 210\u2013222 (2018).","journal-title":"Ann. Neurol."},{"key":"314_CR66","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/1352458515593405","volume":"22","author":"A Pichler","year":"2016","unstructured":"Pichler, A. et al. Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice. Mult. Scler. 22, 340\u2013346 (2016).","journal-title":"Mult. Scler."},{"key":"314_CR67","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s00415-015-7798-0","volume":"262","author":"A Vidal-Jordana","year":"2015","unstructured":"Vidal-Jordana, A., Sastre-Garriga, J., Rovira, A. & Montalban, X. Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. J. Neurol. 262, 2617\u20132626 (2015).","journal-title":"J. Neurol."},{"key":"314_CR68","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(04)17271-1","volume":"364","author":"M Filippi","year":"2004","unstructured":"Filippi, M. et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364, 1489\u20131496 (2004).","journal-title":"Lancet"},{"key":"314_CR69","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/135245850000600601","volume":"6","author":"RA Rudick","year":"2000","unstructured":"Rudick, R. A., Fisher, E., Lee, J. C., Duda, J. T. & Simon, J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult. Scler. 6, 365\u2013372 (2000).","journal-title":"Mult. Scler."},{"key":"314_CR70","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.53.8.1698","volume":"53","author":"RA Rudick","year":"1999","unstructured":"Rudick, R. A., Fisher, E., Lee, J. C., Simon, J. & Jacobs, L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53, 1698\u20131704 (1999).","journal-title":"Neurology"},{"key":"314_CR71","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/1352458515599072","volume":"22","author":"E Fisher","year":"2016","unstructured":"Fisher, E. et al. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: a retrospective analysis. Mult. Scler. 22, 668\u2013676 (2016).","journal-title":"Mult. Scler."},{"key":"314_CR72","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1177\/1352458512473190","volume":"19","author":"A Vidal-Jordana","year":"2013","unstructured":"Vidal-Jordana, A. et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult. Scler. 19, 1175\u20131181 (2013).","journal-title":"Mult. Scler."},{"key":"314_CR73","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/jon.12337","volume":"26","author":"A Vidal-Jordana","year":"2016","unstructured":"Vidal-Jordana, A. et al. Brain volume loss during the first year of interferon-beta treatment in multiple sclerosis: baseline inflammation and regional brain volume dynamics. J. Neuroimaging 26, 532\u2013538 (2016).","journal-title":"J. Neuroimaging"},{"key":"314_CR74","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458512469695","volume":"19","author":"G Comi","year":"2013","unstructured":"Comi, G. et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult. Scler. 19, 1074\u20131083 (2013).","journal-title":"Mult. Scler."},{"key":"314_CR75","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ana.21079","volume":"61","author":"JS Wolinsky","year":"2007","unstructured":"Wolinsky, J. S. et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol. 61, 14\u201324 (2007).","journal-title":"Ann. Neurol."},{"key":"314_CR76","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1177\/1352458509106937","volume":"15","author":"X Montalban","year":"2009","unstructured":"Montalban, X. et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult. Scler. 15, 1195\u20131205 (2009).","journal-title":"Mult. Scler."},{"key":"314_CR77","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","volume":"68","author":"DH Miller","year":"2007","unstructured":"Miller, D. H. et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68, 1390\u20131401 (2007).","journal-title":"Neurology"},{"key":"314_CR78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149685","volume":"11","author":"P Branger","year":"2016","unstructured":"Branger, P., Parienti, J. J., Sormani, M. P. & Defer, G. The effect of disease-modifying drugs on brain atrophy in relapsing-remitting multiple sclerosis: a meta-analysis. PLoS One 11, e0149685 (2016).","journal-title":"PLoS One"},{"key":"314_CR79","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen, J. A. et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380, 1819\u20131828 (2012).","journal-title":"Lancet"},{"key":"314_CR80","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 1829\u20131839 (2012).","journal-title":"Lancet"},{"key":"314_CR81","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402\u2013415 (2010).","journal-title":"N. Engl. J. Med."},{"key":"314_CR82","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s00415-014-7412-x","volume":"261","author":"DL Arnold","year":"2014","unstructured":"Arnold, D. L. et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 DEFINE study. J. Neurol. 261, 1794\u20131802 (2014).","journal-title":"J. Neurol."},{"key":"314_CR83","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1352458517690269","volume":"24","author":"N De Stefano","year":"2018","unstructured":"De Stefano, N. et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult. Scler. 24, 222\u2013226 (2018).","journal-title":"Mult. Scler."},{"key":"314_CR84","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.24018","volume":"75","author":"MP Sormani","year":"2014","unstructured":"Sormani, M. P., Arnold, D. L. & De Stefano, N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann. Neurol. 75, 43\u201349 (2014).","journal-title":"Ann. Neurol."},{"key":"314_CR85","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","volume":"383","author":"J Chataway","year":"2014","unstructured":"Chataway, J. et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383, 2213\u20132221 (2014).","journal-title":"Lancet"},{"key":"314_CR86","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa1803583","volume":"379","author":"RJ Fox","year":"2018","unstructured":"Fox, R. J. et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N. Engl. J. Med. 379, 846\u2013855 (2018).","journal-title":"N. Engl. J. Med."},{"key":"314_CR87","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneurol.2015.80","volume":"11","author":"H Kearney","year":"2015","unstructured":"Kearney, H., Miller, D. H. & Ciccarelli, O. Spinal cord MRI in multiple sclerosis \u2014 diagnostic, prognostic and clinical value. Nat. Rev. Neurol. 11, 327\u2013338 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"314_CR88","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1474-4422(10)70131-9","volume":"9","author":"R Kapoor","year":"2010","unstructured":"Kapoor, R. et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 9, 681\u2013688 (2010).","journal-title":"Lancet Neurol."},{"key":"314_CR89","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/1352458517709954","volume":"24","author":"N Cawley","year":"2018","unstructured":"Cawley, N. et al. Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. Mult. Scler. 24, 932\u2013941 (2018).","journal-title":"Mult. Scler."},{"key":"314_CR90","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1212\/WNL.60.1.44","volume":"60","author":"SM Leary","year":"2003","unstructured":"Leary, S. M. et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 60, 44\u201351 (2003).","journal-title":"Neurology"},{"key":"314_CR91","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","volume":"387","author":"F Lublin","year":"2016","unstructured":"Lublin, F. et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 387, 1075\u20131084 (2016).","journal-title":"Lancet"},{"key":"314_CR92","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/1352458515569099","volume":"21","author":"MP Sormani","year":"2015","unstructured":"Sormani, M. P. et al. Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult. Scler. 21, 916\u2013924 (2015).","journal-title":"Mult. Scler."},{"key":"314_CR93","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1212\/01.WNL.0000036271.49066.06","volume":"59","author":"E Fisher","year":"2002","unstructured":"Fisher, E. et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59, 1412\u20131420 (2002).","journal-title":"Neurology"},{"key":"314_CR94","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1179\/1743132813Y.0000000304","volume":"36","author":"JI Rojas","year":"2014","unstructured":"Rojas, J. I., Patrucco, L., Miguez, J., Besada, C. & Cristiano, E. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis. Neurol. Res. 36, 615\u2013618 (2014).","journal-title":"Neurol. Res."},{"key":"314_CR95","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1212\/WNL.0000000000001281","volume":"84","author":"EW Radue","year":"2015","unstructured":"Radue, E. W. et al. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology 84, 784\u2013793 (2015).","journal-title":"Neurology"},{"key":"314_CR96","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00415-015-7959-1","volume":"263","author":"DR Jeffery","year":"2016","unstructured":"Jeffery, D. R. et al. The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS. J. Neurol. 263, 299\u2013305 (2016).","journal-title":"J. Neurol."},{"key":"314_CR97","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","volume":"22","author":"L Kappos","year":"2016","unstructured":"Kappos, L. et al. Inclusion of brain volume loss in a revised measure of \u2018no evidence of disease activity\u2019 (NEDA-4) in relapsing-remitting multiple sclerosis. Mult. Scler. 22, 1297\u20131305 (2016).","journal-title":"Mult. Scler."},{"key":"314_CR98","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.0000000000006810","volume":"92","author":"C Gasperini","year":"2019","unstructured":"Gasperini, C. et al. Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge. Neurology 92, 180\u2013192 (2019).","journal-title":"Neurology"},{"key":"314_CR99","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1352458517698052","volume":"24","author":"J Rio","year":"2018","unstructured":"Rio, J. et al. Disability progression markers over 6\u201312 years in interferon-beta-treated multiple sclerosis patients. Mult. Scler. 24, 322\u2013330 (2018).","journal-title":"Mult. Scler."},{"key":"314_CR100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2005.06.003","volume":"1","author":"SG Mueller","year":"2005","unstructured":"Mueller, S. G. et al. Ways toward an early diagnosis in Alzheimer\u2019s disease: the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 1, 55\u201366 (2005).","journal-title":"Alzheimers Dement."},{"key":"314_CR101","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.neuroimage.2009.08.008","volume":"49","author":"Z Caramanos","year":"2010","unstructured":"Caramanos, Z. et al. Gradient distortions in MRI: characterizing and correcting for their effects on SIENA-generated measures of brain volume change. Neuroimage 49, 1601\u20131611 (2010).","journal-title":"Neuroimage"},{"key":"314_CR102","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.neuroimage.2005.09.046","volume":"30","author":"J Jovicich","year":"2006","unstructured":"Jovicich, J. et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage 30, 436\u2013443 (2006).","journal-title":"Neuroimage"},{"key":"314_CR103","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuroimage.2006.02.051","volume":"32","author":"X Han","year":"2006","unstructured":"Han, X. et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage 32, 180\u2013194 (2006).","journal-title":"Neuroimage"},{"key":"314_CR104","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2014.37","volume":"1","author":"J Maclaren","year":"2014","unstructured":"Maclaren, J., Han, Z., Vos, S. B., Fischbein, N. & Bammer, R. Reliability of brain volume measurements: a test\u2013retest dataset. Sci. Data 1, 140037 (2014).","journal-title":"Sci. Data"},{"key":"314_CR105","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hbm.20973","volume":"31","author":"RA Morey","year":"2010","unstructured":"Morey, R. A. et al. Scan\u2013rescan reliability of subcortical brain volumes derived from automated segmentation. Hum. Brain Mapp. 31, 1751\u20131762 (2010).","journal-title":"Hum. Brain Mapp."},{"key":"314_CR106","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.neuroimage.2010.03.075","volume":"52","author":"MP Sampat","year":"2010","unstructured":"Sampat, M. P. et al. Disease modeling in multiple sclerosis: assessment and quantification of sources of variability in brain parenchymal fraction measurements. Neuroimage 52, 1367\u20131373 (2010).","journal-title":"Neuroimage"},{"key":"314_CR107","volume":"11","author":"CY Yang","year":"2016","unstructured":"Yang, C. Y. et al. Reproducibility of brain morphometry from short-term repeat clinical MRI examinations: a retrospective study. PLoS One 11, e0146913 (2016).","journal-title":"PLoS One"},{"key":"314_CR108","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.neuroimage.2016.07.035","volume":"142","author":"V Biberacher","year":"2016","unstructured":"Biberacher, V. et al. Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. Neuroimage 142, 188\u2013197 (2016).","journal-title":"Neuroimage"},{"key":"314_CR109","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.neuroimage.2014.12.006","volume":"107","author":"M Reuter","year":"2015","unstructured":"Reuter, M. et al. Head motion during MRI acquisition reduces gray matter volume and thickness estimates. Neuroimage 107, 107\u2013115 (2015).","journal-title":"Neuroimage"},{"key":"314_CR110","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1088\/0031-9155\/61\/5\/R32","volume":"61","author":"F Godenschweger","year":"2016","unstructured":"Godenschweger, F. et al. Motion correction in MRI of the brain. Phys. Med. Biol. 61, R32\u2013R56 (2016).","journal-title":"Phys. Med. Biol."},{"key":"314_CR111","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.neuroimage.2009.02.010","volume":"46","author":"J Jovicich","year":"2009","unstructured":"Jovicich, J. et al. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage 46, 177\u2013192 (2009).","journal-title":"Neuroimage"},{"key":"314_CR112","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuroimage.2010.06.025","volume":"53","author":"J Barnes","year":"2010","unstructured":"Barnes, J. et al. Head size, age and gender adjustment in MRI studies: a necessary nuisance? Neuroimage 53, 1244\u20131255 (2010).","journal-title":"Neuroimage"},{"key":"314_CR113","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nimg.2002.1040","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith, S. M. et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17, 479\u2013489 (2002).","journal-title":"Neuroimage"},{"key":"314_CR114","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.nicl.2018.04.023","volume":"19","author":"H Amiri","year":"2018","unstructured":"Amiri, H. et al. Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. Neuroimage Clin. 19, 466\u2013475 (2018).","journal-title":"Neuroimage Clin."},{"key":"314_CR115","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1212\/01.WNL.0000161871.83614.BB","volume":"64","author":"C Enzinger","year":"2005","unstructured":"Enzinger, C. et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 64, 1704\u20131711 (2005).","journal-title":"Neurology"},{"key":"314_CR116","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuroimage.2015.03.035","volume":"112","author":"MA Fraser","year":"2015","unstructured":"Fraser, M. A., Shaw, M. E. & Cherbuin, N. A systematic review and meta-analysis of longitudinal hippocampal atrophy in healthy human ageing. Neuroimage 112, 364\u2013374 (2015).","journal-title":"Neuroimage"},{"key":"314_CR117","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neubiorev.2013.12.004","volume":"39","author":"AN Ruigrok","year":"2014","unstructured":"Ruigrok, A. N. et al. A meta-analysis of sex differences in human brain structure. Neurosci. Biobehav. Rev. 39, 34\u201350 (2014).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"314_CR118","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11682-015-9468-3","volume":"10","author":"A Kiraly","year":"2016","unstructured":"Kiraly, A. et al. Male brain ages faster: the age and gender dependence of subcortical volumes. Brain Imaging Behav. 10, 901\u2013910 (2016).","journal-title":"Brain Imaging Behav."},{"key":"314_CR119","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1006\/nimg.2001.0857","volume":"14","author":"CD Good","year":"2001","unstructured":"Good, C. D. et al. Cerebral asymmetry and the effects of sex and handedness on brain structure: a voxel-based morphometric analysis of 465 normal adult human brains. Neuroimage 14, 685\u2013700 (2001).","journal-title":"Neuroimage"},{"key":"314_CR120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/hbm.20187","volume":"27","author":"E Luders","year":"2006","unstructured":"Luders, E. et al. Gender effects on cortical thickness and the influence of scaling. Hum. Brain Mapp. 27, 314\u2013324 (2006).","journal-title":"Hum. Brain Mapp."},{"key":"314_CR121","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1007\/s00429-016-1193-1","volume":"221","author":"T De Bondt","year":"2016","unstructured":"De Bondt, T., Pullens, P., Van Hecke, W., Jacquemyn, Y. & Parizel, P. M. Reproducibility of hormone-driven regional grey matter volume changes in women using SPM8 and SPM12. Brain Struct. Funct. 221, 4631\u20134641 (2016).","journal-title":"Brain Struct. Funct."},{"key":"314_CR122","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neuroimage.2015.05.077","volume":"118","author":"K Nakamura","year":"2015","unstructured":"Nakamura, K. et al. Diurnal fluctuations in brain volume: statistical analyses of MRI from large populations. Neuroimage 118, 126\u2013132 (2015).","journal-title":"Neuroimage"},{"key":"314_CR123","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/01.WNL.0000150542.16969.CC","volume":"64","author":"T Duning","year":"2005","unstructured":"Duning, T. et al. Dehydration confounds the assessment of brain atrophy. Neurology 64, 548\u2013550 (2005).","journal-title":"Neurology"},{"key":"314_CR124","doi-asserted-by":"crossref","first-page":"482536","DOI":"10.1155\/2015\/482536","volume":"2015","author":"RE Klaren","year":"2015","unstructured":"Klaren, R. E. et al. Objectively measured physical activity is associated with brain volumetric measurements in multiple sclerosis. Behav. Neurol. 2015, 482536 (2015).","journal-title":"Behav. Neurol."},{"key":"314_CR125","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/jnnp.2006.095869","volume":"78","author":"S Mechtcheriakov","year":"2007","unstructured":"Mechtcheriakov, S. et al. A widespread distinct pattern of cerebral atrophy in patients with alcohol addiction revealed by voxel-based morphometry. J. Neurol. Neurosurg. Psychiatry 78, 610\u2013614 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"314_CR126","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.drugalcdep.2015.06.016","volume":"155","author":"Y Mashhoon","year":"2015","unstructured":"Mashhoon, Y., Sava, S., Sneider, J. T., Nickerson, L. D. & Silveri, M. M. Cortical thinness and volume differences associated with marijuana abuse in emerging adults. Drug Alcohol Depend. 155, 275\u2013283 (2015).","journal-title":"Drug Alcohol Depend."},{"key":"314_CR127","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1097\/HJH.0b013e32836184b5","volume":"31","author":"O Beauchet","year":"2013","unstructured":"Beauchet, O. et al. Blood pressure levels and brain volume reduction: a systematic review and meta-analysis. J. Hypertens. 31, 1502\u20131516 (2013).","journal-title":"J. Hypertens."},{"key":"314_CR128","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jamapsychiatry.2016.0274","volume":"73","author":"B Hooshmand","year":"2016","unstructured":"Hooshmand, B. et al. Association of vitamin B12, folate, and sulfur amino acids with brain magnetic resonance imaging measures in older adults: a longitudinal population-based study. JAMA Psychiatry 73, 606\u2013613 (2016).","journal-title":"JAMA Psychiatry"},{"key":"314_CR129","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1352458517736149","volume":"25","author":"A Pichler","year":"2019","unstructured":"Pichler, A. et al. The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis. Mult. Scler. 25, 48\u201354 (2019).","journal-title":"Mult. Scler."},{"key":"314_CR130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jmri.22214","volume":"32","author":"DT Chard","year":"2010","unstructured":"Chard, D. T., Jackson, J. S., Miller, D. H. & Wheeler-Kingshott, C. A. Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J. Magn. Reson. Imaging 32, 223\u2013228 (2010).","journal-title":"J. Magn. Reson. Imaging"},{"key":"314_CR131","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/hbm.21344","volume":"33","author":"M Battaglini","year":"2012","unstructured":"Battaglini, M., Jenkinson, M. & De Stefano, N. Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum. Brain Mapp. 33, 2062\u20132071 (2012).","journal-title":"Hum. Brain Mapp."},{"key":"314_CR132","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archneurol.2011.674","volume":"69","author":"J Cheriyan","year":"2012","unstructured":"Cheriyan, J., Kim, S., Wolansky, L. J., Cook, S. D. & Cadavid, D. Impact of inflammation on brain volume in multiple sclerosis. Arch. Neurol. 69, 82\u201388 (2012).","journal-title":"Arch. Neurol."},{"key":"314_CR133","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/01.wnl.0000316810.01120.05","volume":"71","author":"R Zivadinov","year":"2008","unstructured":"Zivadinov, R. et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71, 136\u2013144 (2008).","journal-title":"Neurology"},{"key":"314_CR134","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2018172468","volume":"288","author":"L Storelli","year":"2018","unstructured":"Storelli, L. et al. Measurement of whole-brain and gray matter atrophy in multiple sclerosis: assessment with MR imaging. Radiology 288, 554\u2013564 (2018).","journal-title":"Radiology"},{"key":"314_CR135","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuroimage.2005.02.018","volume":"26","author":"J Ashburner","year":"2005","unstructured":"Ashburner, J. & Friston, K. J. Unified segmentation. Neuroimage 26, 839\u2013851 (2005).","journal-title":"Neuroimage"},{"key":"314_CR136","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1109\/TMI.2015.2418298","volume":"34","author":"MJ Cardoso","year":"2015","unstructured":"Cardoso, M. J. et al. Geodesic information flows: spatially-variant graphs and their application to segmentation and fusion. IEEE Trans. Med. Imaging 34, 1976\u20131988 (2015).","journal-title":"IEEE Trans. Med. Imaging"},{"key":"314_CR137","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12021-011-9109-y","volume":"9","author":"BB Avants","year":"2011","unstructured":"Avants, B. B., Tustison, N. J., Wu, J., Cook, P. A. & Gee, J. C. An open source multivariate framework for n-tissue segmentation with evaluation on public data. Neuroinformatics 9, 381\u2013400 (2011).","journal-title":"Neuroinformatics"},{"key":"314_CR138","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/nimg.1998.0396","volume":"9","author":"B Fischl","year":"1999","unstructured":"Fischl, B., Sereno, M. I. & Dale, A. M. Cortical surface-based analysis. II: inflation, flattening, and a surface-based coordinate system. Neuroimage 9, 195\u2013207 (1999).","journal-title":"Neuroimage"},{"key":"314_CR139","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/nimg.1999.0534","volume":"12","author":"D MacDonald","year":"2000","unstructured":"MacDonald, D., Kabani, N., Avis, D. & Evans, A. C. Automated 3-D extraction of inner and outer surfaces of cerebral cortex from MRI. Neuroimage 12, 340\u2013356 (2000).","journal-title":"Neuroimage"},{"key":"314_CR140","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/jmri.1880070620","volume":"7","author":"NC Fox","year":"1997","unstructured":"Fox, N. C. & Freeborough, P. A. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer\u2019s disease. J. Magn. Reson. Imaging 7, 1069\u20131075 (1997).","journal-title":"J. Magn. Reson. Imaging"},{"key":"314_CR141","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuroimage.2013.12.004","volume":"90","author":"MG Dwyer","year":"2014","unstructured":"Dwyer, M. G., Bergsland, N. & Zivadinov, R. Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. Neuroimage 90, 207\u2013217 (2014).","journal-title":"Neuroimage"},{"key":"314_CR142","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/hbm.23828","volume":"39","author":"M Battaglini","year":"2018","unstructured":"Battaglini, M., Jenkinson, M. & De Stefano, N. SIENA-XL for improving the assessment of gray and white matter volume changes on brain MRI. Hum. Brain Mapp. 39, 1063\u20131077 (2018).","journal-title":"Hum. Brain Mapp."},{"key":"314_CR143","first-page":"197","volume":"6","author":"J Ashburner","year":"2012","unstructured":"Ashburner, J. & Ridgway, G. R. Symmetric diffeomorphic modeling of longitudinal structural MRI. Front. Neurosci. 6, 197 (2012).","journal-title":"Front. Neurosci."},{"key":"314_CR144","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.nicl.2013.10.015","volume":"4","author":"K Nakamura","year":"2014","unstructured":"Nakamura, K. et al. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. Neuroimage Clin. 4, 10\u201317 (2014).","journal-title":"Neuroimage Clin."},{"key":"314_CR145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuroimage.2011.02.076","volume":"57","author":"M Reuter","year":"2011","unstructured":"Reuter, M. & Fischl, B. Avoiding asymmetry-induced bias in longitudinal image processing. Neuroimage 57, 19\u201321 (2011).","journal-title":"Neuroimage"},{"key":"314_CR146","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.neuroimage.2010.07.052","volume":"54","author":"K Nakamura","year":"2011","unstructured":"Nakamura, K., Fox, R. & Fisher, E. CLADA: cortical longitudinal atrophy detection algorithm. Neuroimage 54, 278\u2013289 (2011).","journal-title":"Neuroimage"},{"key":"314_CR147","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s00415-016-8133-0","volume":"263","author":"M Amann","year":"2016","unstructured":"Amann, M. et al. Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial). J. Neurol. 263, 1364\u20131374 (2016).","journal-title":"J. Neurol."},{"key":"314_CR148","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuroimage.2016.10.009","volume":"145","author":"B De Leener","year":"2017","unstructured":"De Leener, B. et al. SCT: spinal cord toolbox, an open-source software for processing spinal cord MRI data. Neuroimage 145, 24\u201343 (2017).","journal-title":"Neuroimage"},{"key":"314_CR149","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nicl.2015.05.003","volume":"8","author":"S Jain","year":"2015","unstructured":"Jain, S. et al. Automatic segmentation and volumetry of multiple sclerosis brain lesions from MR images. Neuroimage Clin. 8, 367\u2013375 (2015).","journal-title":"Neuroimage Clin."},{"key":"314_CR150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1176\/appi.neuropsych.11120377","volume":"25","author":"DE Ross","year":"2013","unstructured":"Ross, D. E., Ochs, A. L., Seabaugh, J. M. & Shrader, C. R. Man versus machine: comparison of radiologists\u2019 interpretations and NeuroQuant\u00ae volumetric analyses of brain MRIs in patients with traumatic brain injury. J. Neuropsychiatry Clin. Neurosci. 25, 32\u201339 (2013).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"314_CR151","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1155\/2009\/616581","volume":"21","author":"JB Brewer","year":"2009","unstructured":"Brewer, J. B. Fully-automated volumetric MRI with normative ranges: translation to clinical practice. Behav. Neurol. 21, 21\u201328 (2009).","journal-title":"Behav. Neurol."},{"key":"314_CR152","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.mri.2015.12.031","volume":"34","author":"R Opfer","year":"2016","unstructured":"Opfer, R. et al. Atlas based brain volumetry: how to distinguish regional volume changes due to biological or physiological effects from inherent noise of the methodology. Magn. Reson. Imaging 34, 455\u2013461 (2016).","journal-title":"Magn. Reson. Imaging"},{"key":"314_CR153","doi-asserted-by":"crossref","first-page":"8323","DOI":"10.1088\/0031-9155\/58\/23\/8323","volume":"58","author":"L Spies","year":"2013","unstructured":"Spies, L. et al. Fully automatic detection of deep white matter T1 hypointense lesions in multiple sclerosis. Phys. Med. Biol. 58, 8323\u20138337 (2013).","journal-title":"Phys. Med. Biol."},{"key":"314_CR154","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.nicl.2017.06.034","volume":"15","author":"MD Steenwijk","year":"2017","unstructured":"Steenwijk, M. D. et al. Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy. Neuroimage Clin. 15, 843\u2013853 (2017).","journal-title":"Neuroimage Clin."},{"key":"314_CR155","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/jnnp-2013-306289","volume":"85","author":"N De Stefano","year":"2014","unstructured":"De Stefano, N. et al. Efficacy of subcutaneous interferon beta-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J. Neurol. Neurosurg. Psychiatry 85, 647\u2013653 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"314_CR156","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1212\/01.wnl.0000237994.95410.ce","volume":"67","author":"L Kappos","year":"2006","unstructured":"Kappos, L. et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 67, 944\u2013953 (2006).","journal-title":"Neurology"},{"key":"314_CR157","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","volume":"370","author":"L Kappos","year":"2007","unstructured":"Kappos, L. et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370, 389\u2013397 (2007).","journal-title":"Lancet"},{"key":"314_CR158","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/brain\/123.11.2256","volume":"123","author":"PD Molyneux","year":"2000","unstructured":"Molyneux, P. D. et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 123, 2256\u20132263 (2000).","journal-title":"Brain"},{"key":"314_CR159","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","volume":"374","author":"G Comi","year":"2009","unstructured":"Comi, G. et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374, 1503\u20131511 (2009).","journal-title":"Lancet"},{"key":"314_CR160","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1212\/01.WNL.0000120663.85143.B3","volume":"62","author":"MP Sormani","year":"2004","unstructured":"Sormani, M. P. et al. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 62, 1432\u20131434 (2004).","journal-title":"Neurology"},{"key":"314_CR161","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","volume":"13","author":"AE Miller","year":"2014","unstructured":"Miller, A. E. et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 13, 977\u2013986 (2014).","journal-title":"Lancet Neurol."},{"key":"314_CR162","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O\u2019Connor","year":"2011","unstructured":"O\u2019Connor, P. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365, 1293\u20131303 (2011).","journal-title":"N. Engl. J. Med."},{"key":"314_CR163","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/1352458513475723","volume":"19","author":"JS Wolinsky","year":"2013","unstructured":"Wolinsky, J. S. et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult. Scler. 19, 1310\u20131319 (2013).","journal-title":"Mult. Scler."},{"key":"314_CR164","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000390","volume":"4","author":"EW Radue","year":"2017","unstructured":"Radue, E. W. et al. Teriflunomide slows BVL in relapsing MS: a reanalysis of the TEMSO MRI data set using SIENA. Neurol. Neuroimmunol. Neuroinflamm. 4, e390 (2017).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"314_CR165","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.0000000000001360","volume":"84","author":"DH Miller","year":"2015","unstructured":"Miller, D. H. et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology 84, 1145\u20131152 (2015).","journal-title":"Neurology"},{"key":"314_CR166","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jns.2010.02.012","volume":"292","author":"EW Radue","year":"2010","unstructured":"Radue, E. W. et al. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J. Neurol. Sci. 292, 28\u201335 (2010).","journal-title":"J. Neurol. Sci."},{"key":"314_CR167","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","volume":"17","author":"R Kapoor","year":"2018","unstructured":"Kapoor, R. et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 17, 405\u2013415 (2018).","journal-title":"Lancet Neurol."},{"key":"314_CR168","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/archneurol.2012.1051","volume":"69","author":"EW Radue","year":"2012","unstructured":"Radue, E. W. et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch. Neurol. 69, 1259\u20131269 (2012).","journal-title":"Arch. Neurol."},{"key":"314_CR169","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi, P. A. et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 13, 545\u2013556 (2014).","journal-title":"Lancet Neurol."},{"key":"314_CR170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"314_CR171","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban, X. et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 376, 209\u2013220 (2017).","journal-title":"N. Engl. J. Med."},{"key":"314_CR172","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","volume":"13","author":"TP Leist","year":"2014","unstructured":"Leist, T. P. et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 13, 257\u2013267 (2014).","journal-title":"Lancet Neurol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41582-020-0314-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-020-0314-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-020-0314-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T20:55:37Z","timestamp":1722459337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-0314-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":172,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1038\/s41582-020-0314-x","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"17 January 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S.-G. declares grants and personal fees from Genzyme, personal fees from Almirall, Biogen, Celgene, Merck, Novartis, Roche and Teva and is a member of the Editorial Committee of <i>Multiple Sclerosis Journal<\/i> and Director of the Scientific Committee of <i>Revista de Neurologia<\/i>, all unrelated to this Consensus Statement. D.P. declares personal fees from Novartis and Sanofi-Genzyme, unrelated to this Consensus Statement. M.A.R. declares personal fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis and Teva, all unrelated to this Consensus Statement. O.C. declares grants from the Spinal Cord Research Foundation, the Rosetree Trust, the Progressive MS Alliance, Bioclinica, GE Neuro, EU-H2020, the UK MS Society, the National MS Society, and the National Institute for Health Research Biomedical Research Centre, University College London Hospitals, and declares personal fees from Merck, <i>Neurology<\/i>, Novartis, Roche and Teva, all unrelated to this Consensus Statement. O.C. also declares grants from the UK MS Society, the National Institute for Health Research Biomedical Research Centre, University College London Hospitals, and the National MS Society during the course of this Consensus Statement. C.E. declares personal fees from Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Roche, Sanofi-Aventis, Shire and Teva, all unrelated to this Consensus Statement. J.W. declares employment with Medical Image Analysis Center, scientific advisory board membership for Biogen, Genzyme, Novartis, TEVA and Roche, personal fees from Bayer, Novartis and Roche, and grants from the European Union (Horizon2020), German Federal Ministries of Education and Research (BMBF), and Economic Affairs and Energy (BMWI), all unrelated to this Consensus Statement. M.P.S. declares personal fees from Actelion, Biogen, Genzyme, Merck, Novartis, Roche, Serono, Synthon and Teva, all unrelated to this Consensus Statement. F.B. acts as a consultant for Apitope, Bayer-Schering, Biogen-Idec, GeNeuro, Sanofi-Genzyme, Ixico, Janssen Research, Merck-Serono, Novartis, Roche and TEVA. He has received grants, or grants are pending, from the Amyloid Imaging to Prevent Alzheimer\u2019s Disease (AMYPAD) initiative, the Biomedical Research Centre at University College London Hospitals, the Dutch MS Society, ECTRIMS\u2013MAGNIMS, EU-H2020, the Dutch Research Council (NWO), the UK MS Society, and the National Institute for Health Research, University College London. He has received payments for the development of educational presentations from Ixico and to his institution from Biogen-Idec. He is on the editorial board of <i>Radiology<\/i>, <i>Brain<\/i>, <i>European Radiology<\/i>, <i>Multiple Sclerosis Journal<\/i> and <i>Neurology<\/i>. T.A.Y. declares research support from Biogen, GlaxoSmithKline, Novartis and Schering, and honoraria from Bayer Schering, Biogen, Hikma and Novartis. N.D.S. declares personal fees from Biogen-Idec, Celgene, Sanofi-Genzyme, Merck Serono, Novartis, Roche and Teva, grants from Merck Serono, Novartis and the Italian MS Society, and nonfinancial support from Biogen-Idec, Sanofi-Genzyme, Merck Serono, Novartis, Roche and Teva, all unrelated to this Consensus Statement. M.T. declares personal fees from Almirall, Bayer Healthcare, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi-Genzyme and Teva, grants from Sanofi-Genzyme, and other competing interests related to Biogen Idec, all unrelated to this Consensus Statement. M.F. declares personal fees from Biogen Idec, Merck-Serono, Novartis and Teva, and grants from Biogen Idec, Merck-Serono, Novartis, Roche and Teva, all unrelated to this Consensus Statement. He is the Editor-in-Chief of the <i>Journal of Neurology<\/i>. C.G. declares advisory board membership for Biogen, Genzyme, Merck-Serono, Roche and Teva, and honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche and Teva. L.K. declares competing interests related to Actelion, Almirall, Alkermes, Bayer, Biogen, df-mp, The European Union, Excemed, GeNeuro, Genzyme, Japan Tobacco, Merck, Minoryx, Mitsubishi Pharma, Neurostatus, Novartis, Receptos\u2013Celgene, Roche, Roche Research Foundations, Sanofi-Aventis, Santhera, the Swiss Multiple Sclerosis Society, Swiss National Research Foundation, Teva and Vianex, all unrelated to this Consensus Statement. J.R. declares personal fees from Biogen, Merck, Novartis and Roche, and other competing interests related to Merck and Mylan, all unrelated to this Consensus Statement. J.F. declares personal fees from Biogen Idec, Merck Serono and Sanofi-Aventis, participation in scientific advisory boards for Almiral, Genzyme and Novartis, personal fees (speaker honoraria) from Biogen Idec, Merck Serono, Santhera and Teva, and participation as an advisor on preclinical development for Takeda, all unrelated to this Consensus Statement. J.P. declares grants and personal fees from Alexion, Biogen Idec, Chugai, and Merck Serono, personal fees from ABIDE, ARGENX, Med Day, Novartis, Roche and Teva, and grants from ABIDE and MedImmun, all unrelated to this Consensus Statement. She also has a patent (patent number 13704627.2-1408) with Isis: Diagnosing Multiple Sclerosis. H.V. declares grants from Merck Serono, Novartis and Teva, and other competing interests related to Merck and Novartis, all unrelated to this Consensus Statement. He also has a patent related to brain atrophy measurement pending. X.M. declares personal fees from Actelion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, all unrelated to this Consensus Statement. \u00c0.R. declares personal fees from Bayer, Biogen, Icometrix, Merck Serono, Novartis, Sanofi-Genzyme, Roche and Teva, and other competing interests related to Bayer, Novartis, OLEA Medical, Sanofi-Genzyme and Synthetic MRI, all unrelated to this Consensus Statement. M.B. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}